Nanoparticle-based delivery systems could optimize SH003 dosing and tumor targeting, while combinatorial approaches with CAR-T cells, PD-1/PD-L1 blockade, or STING agonists may potentiate cytotoxic T-cell activity and overcome microenvironmental resistance. The gene discussed is CD274; the disease is neoplasm.